1. Enucleation of the Prostate for the Treatment of Benign Prostatic Hyperplasia Using a 980 nm Diode Laser
- Author
-
Wanli Cheng, Yaqun Zhang, Xinda Song, Chunlong Fu, Huimin Hou, Ming Liu, Jianye Wang, Xin Chen, Pengjie Wu, and Jinfu Wang
- Subjects
Male ,medicine.medical_specialty ,General Chemical Engineering ,Enucleation ,Population ,Prostatic Hyperplasia ,Urology ,General Biochemistry, Genetics and Molecular Biology ,Resection ,law.invention ,Prostate ,law ,Lower urinary tract symptoms ,Humans ,Medicine ,Intraoperative Complications ,education ,Diode ,education.field_of_study ,General Immunology and Microbiology ,business.industry ,General Neuroscience ,Length of Stay ,Hyperplasia ,Laser ,medicine.disease ,Treatment Outcome ,medicine.anatomical_structure ,Quality of Life ,Laser Therapy ,Lasers, Semiconductor ,business - Abstract
In the aging male population, the occurrence of lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH) is a common problem. Here, we introduce a new technique called 980 nm diode laser enucleation (DiLEP) to treat BPH1. Diode lasers can absorb both water and hemoglobin at the same time, so they are good for cutting and hemostasis2. The diode laser was approved by the FDA in 2007, and has been used in the treatment of BPH because of its effective cutting and hemostasis effect3. DiLEP presents several advantages over other techniques, such as TURP, HoLEP, and PVP. During the procedure, we define the boundary of a high-volume prostate and separate it into three lobes with a diode laser by burning two rings and one groove (like a Cupid's arrow). Compared to other procedures, mDiLEP has fewer intraoperative complications, a shorter learning curve, and achieves more tissue resection.
- Published
- 2020